Lv4
710 积分 2022-08-03 加入
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
20小时前
待确认
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review
22小时前
待确认
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
2天前
已完结
Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma
3天前
已完结
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
3天前
已完结
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
4天前
已完结
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
4天前
已完结
Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities
5天前
已完结
Evolving strategies in the management of transplant-eligible patients with newly diagnosed multiple myeloma
5天前
已完结
Novel drug combinations for newly diagnosed multiple myeloma: how can we improve on current regimens?
5天前
已完结
皖公网安备34019202002308
